Sandra and Edward Meyer Cancer Center

A simple blood test that measures the number of lymphocytes, a type of white blood cell in the body, may predict whether people who have relapsed multiple myeloma are going to respond well to CAR-T immunotherapy, according to new research.

Scientists from Weill Cornell Medicine and the Dana-Farber Cancer Institute in Boston have developed and tested new artificial intelligence (AI) tools tailored to digital pathology—a rapidly growing field that uses high-resolution digital images created from tissue samples to help diagnose disease and guide treatment.

Researchers at Weill Cornell Medicine with an international team have used liver biopsies to identify cellular and molecular markers that can potentially be used to predict whether and when pancreatic cancer will spread to an individual’s liver or to another organ.

Before a cell commits fully to the process of dividing itself into two new cells, it may ensure the appropriateness of its commitment by staying for many hours—sometimes more than a day—in a reversible intermediate state, according to a discovery by researchers at Weill Cornell Medicine. 

Weill Cornell Medicine received a $1.5 million grant from the U.S. Department of Defense Prostate Cancer Research Program to develop new approaches for predicting the spread of cancer to the bone in men with prostate cancer at early stages of the disease.

Dr. Ashley Laughney, an assistant professor of physiology and biophysics at Weill Cornell Medicine, has won a 2024 Pershing Square Sohn Prize for Young Investigators in Cancer Research.

An artificial intelligence-powered method for detecting tumor DNA in blood has shown unprecedented sensitivity in predicting cancer recurrence, in a study led by researchers at Weill Cornell Medicine, NewYork-Presbyterian, the New York Genome Center and Memorial Sloan Kettering Cancer Center.

Molecular and physiological changes in space travelers reveal new targets for aerospace medicine and can guide new missions, according to the results of a massive international research endeavor by investigators at Weill Cornell Medicine, SpaceX, and other organizations.

Researchers find that including BRCA1 testing at the time of obstetrical prenatal carrier screening may be a cost-effective way to identify those at risk of certain cancers.

Research led by Weill Cornell Medicine provides new evidence that most colorectal cancers begin with the loss of intestinal stem cells, even before cancer-causing genetic alterations appear.

A team co-led by researchers at Weill Cornell Medicine and the New York Genome Center has developed an advanced method for revealing how gene mutations disrupt the normal packaging of DNA. 

A collaboration between Dr. Jedd Wolchok, the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, and Dr. Yelena Janjigian, chief of the gastrointestinal oncology service at Memorial Sloan Kettering Cancer Center, is looking to transform the care of gastroesophageal cancer (GEC) patients with untreatable disease – earning the pair a grant from Stand Up To Cancer® (SU2C) as a part of the SU2C-Torrey Coast Foundation Gastroesophageal Cancer Dream Team Collective.

Male breast cancer has distinct alterations in the tumor genome that may suggest potential treatment targets, according to a study by Weill Cornell Medicine investigators.

A new study identified a set of 140 genes that may help predict enhanced disease-free survival in patients with non-small cell lung cancer (NSCLC) treated with a combination of immunotherapy and low-dose radiation.

Researchers at Weill Cornell Medicine have uncovered steps that lead to lung tumors called adenocarcinoma turning into a much more aggressive small cell lung cancer that spreads rapidly and has few options for treatment. This problematic process is sometimes seen when patients stop responding to initially effective treatments. The findings advance the understanding of how mutated genes can trigger cancer evolution and suggest targets for more effective treatments.

A new study reported that SARS-CoV-2, the virus that causes COVID, can infect dopamine neurons in the brain and trigger senescence—when a cell loses the ability to grow and divide.

Non-cancerous cells called stromal cells, which are found in and around prostate tumors, may be useful in assessing these tumors’ potential to spread, and may even be targets for future prostate cancer treatments, according to a study led by researchers at Weill Cornell Medicine.

A new study reported that patients with non-small cell lung cancer (NSCLC) treated with a combination of low-dose radiation and immunotherapy had higher progression-free survival compared to patients who received immunotherapy alone two years after treatment. 

Weill Cornell Medicine researchers received a $2.4 million grant from the U.S. Department of Defense Breast Cancer Research Program to validate a new blood test for the early detection of breast cancer.

The Parker Institute for Cancer Immunotherapy (PICI) announced it has added Weill Cornell Medicine to its network of preeminent academic and medical research institutions at the forefront of the fight against cancer.